Haem (baseline; μM) Treatment Haem (μM)
4 h 8 h
4.80 ± 0.63 Control 14.65 ± 0.90* 30.18  ± 3.89*#
BV (10 μM) 16.88 ± 1.59* 27.01 ± 1.94*#
BV (50 μM) 15.41 ± 1.38* 32.24 ± 3.43 *#
LPS 16.69 ± 1.82* 36.25 ± 2.93*#
LPS+BV (10 μM) 17.30 ± 2.77* 28.00 ± 3.34*
LPS+BV  (50 μM) 16.14 ± 1.62* 33.86 ± 4.84*#
UCB (baseline; μM) Treatment UCB (μM)
4 h 8 h
5.23 ± 1.41 Control 11.32 ± 2.03 9.69± 2.32
BV (10 μM) 11.68 ± 1.98 12.85 ± 2.70*
BV (50 μM) 14.40  ± 2.93* 15.56 ± 3.02*
LPS 10.14 ± 3.36 9.50 ± 1.73
LPS+BV (10 μM) 12.42 ± 4.11* 13.31 ± 4.30*
LPS+BV  (50 μM) 12.56 ± 2.35* 13.72 ± 2.90*
Table 3: Unconjugated bilirubin (UCB) and haem concentrations in subjects after 0 (baseline), 4 and 8 h incubation with BV ± LPS (N=7/group).